GRO1 inhibitors are a distinct class of chemical compounds that function by targeting and inhibiting the activity of the Growth-regulated oncogene 1 (GRO1) protein. GRO1, also known as CXCL1, is a chemokine involved in various cellular processes including cell proliferation, migration, and angiogenesis. The inhibition of GRO1 can result in the modulation of signaling pathways that regulate these fundamental cellular activities. GRO1 inhibitors typically achieve this by binding to the GRO1 protein or its receptor, CXCR2, thereby blocking the interaction and subsequent downstream signaling cascades. This blockade can alter the expression of various genes and proteins involved in the regulation of the cell cycle, apoptosis, and other cellular mechanisms.
In the realm of biochemical research, GRO1 inhibitors are instrumental in elucidating the underlying mechanisms of GRO1-related cellular processes. They serve as crucial tools in studying the regulatory networks influenced by GRO1 and its associated signaling pathways. By modulating GRO1 activity, researchers can gain insights into the protein's role in cellular dynamics and its broader implications in tissue homeostasis and pathology. Moreover, GRO1 inhibitors are often employed in various experimental models to investigate the effects of GRO1 inhibition on cell behavior, including changes in gene expression profiles, alterations in cellular morphology, and impacts on cell-cell communication. Through such studies, GRO1 inhibitors contribute significantly to our understanding of the molecular basis of cellular functions and the intricate web of signaling pathways governing these processes.
| Produkt | CAS # | Katalog # | Menge | Preis | Referenzen | Bewertung |
|---|---|---|---|---|---|---|
Reparixin | 266359-83-5 | sc-507446 | 5 mg | ¥880.00 | ||
Reparixin ist ein niedermolekularer Antagonist, der auf den Rezeptor CXCR1 abzielt, der der primäre Rezeptor für CXCL1 ist. Es hat hemmende Wirkungen auf CXCL1-induzierte Entzündungen und die Rekrutierung von Neutrophilen gezeigt. | ||||||
AZD 5069 | 878385-84-3 | sc-507447 | 5 mg | ¥2595.00 | ||
AZD5069 ist ein selektiver niedermolekularer Antagonist von CXCR1. Er hat hemmende Wirkungen auf die CXCL1-vermittelte Neutrophilenmigration gezeigt und wurde bei entzündlichen Lungenerkrankungen untersucht. | ||||||
SB 225002 | 182498-32-4 | sc-202803 sc-202803A | 1 mg 5 mg | ¥406.00 ¥1151.00 | 2 | |
SB225002 ist ein niedermolekularer Antagonist, der auf CXCRIt abzielt und eine hemmende Wirkung auf die CXCL1-induzierte Neutrophilenaktivierung und -migration gezeigt hat. | ||||||